Related Experiment Video
Updated: Mar 15, 2026

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner
Kati Kemppainen1, Nina Wentus1, Taru Lassila1
1Department of Biosciences, Åbo Akademi University; Tykistökatu 6, 20520 Turku, Finland.
Abstract:
Sphingosylphosphorylcholine (SPC) is a bioactive sphingolipid which regulates many cancer-related processes, including cellular proliferation. The Hippo signaling pathway consists of a cascade of tumor suppressive kinases Mst1/2 and Lats1/2 and their downstream targets YAP and TAZ which are generally pro-proliferative transcriptional regulators. Direct phosphorylation by Lats1/2 causes inhibition or degradation of YAP/TAZ and down-regulation of their target genes. We found SPC treatment of MDA-MB-435S breast cancer cells to strongly inhibit their proliferation and to induce a sustained Lats2 protein expression (6-24h). Therefore, we hypothesized that Hippo signaling might mediate the anti-proliferative SPC response. We also saw a cell density-dependent increase in S127-phosphorylated YAP (pS127-YAP) and a decrease in mRNA levels of YAP target genes (CTGF, Cyr61) in response to long (9h) SPC treatment. Knockdown of S1P receptor 2 (S1P2) prevented the SPC-induced up-regulation of Lats2 and attenuated the anti-proliferative effect of SPC. However, while knockdown of Lats2 alone or in combination with Lats1 expectedly increased basal proliferation it did not attenuate the SPC-induced inhibition of proliferation. Exogenous expression of wild-type or kinase-dead Lats2 and knockdown of YAP/TAZ also had no effect on the anti-proliferative SPC response. It has been previously shown that activation of S1P2-G12/13 by sphingosine-1-phosphate (S1P) leads to rapid de-phosphorylation and up-regulation of YAP. Similarly, we saw a decrease in pS127-YAP and an increase in total YAP levels with short (1h) SPC treatment as well as a subsequent transient increase in YAP target gene expression. Inhibition of S1P2 prevented the SPC-induced YAP de-phosphorylation. The rapid YAP activation and subsequent up-regulation of Lats2 mRNA does not constitute a negative feedback loop as knockdown of YAP/TAZ did not inhibit SPC-induced Lats2 expression. In conclusion, in this study we show that SPC is able to regulate Hippo signaling in a dual and opposite manner, causing an initial activation of YAP followed by an inhibition. However, even the strong SPC-induced effects seen in Lats2 and YAP did not mediate the anti-proliferative SPC response.
Insights
Sphingosylphosphorylcholine (SPC) inhibits breast cancer cell proliferation, initially activating then inhibiting the Hippo-YAP pathway. However, this pathway modulation does not mediate SPC's anti-proliferative effects.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Sphingosylphosphorylcholine (SPC) is a bioactive sphingolipid regulating cancer cell proliferation.
- The Hippo pathway, involving Lats1/2 kinases and YAP/TAZ transcriptional regulators, plays a crucial role in cell growth control.
- Dysregulation of the Hippo pathway is implicated in various cancers, making it a target for therapeutic intervention.
Purpose of the Study:
- To investigate whether the Hippo signaling pathway mediates the anti-proliferative effects of SPC in MDA-MB-435S breast cancer cells.
- To elucidate the dual role of SPC in regulating Hippo pathway components, YAP and Lats2.
- To determine the contribution of S1P receptor 2 (S1P2) in mediating SPC's effects on Hippo signaling and proliferation.
Main Methods:
- Treatment of MDA-MB-435S breast cancer cells with SPC.
- Assessment of cell proliferation rates.
- Analysis of Lats2 protein expression and YAP phosphorylation (pS127-YAP) via Western blotting.
- Measurement of YAP target gene mRNA levels (CTGF, Cyr61) using RT-qPCR.
- Gene knockdown experiments using siRNA targeting S1P2, Lats1, Lats2, YAP, and TAZ.
- Pharmacological inhibition of S1P2.
Main Results:
- SPC treatment strongly inhibited breast cancer cell proliferation and induced sustained Lats2 protein expression.
- SPC caused a cell density-dependent increase in pS127-YAP and decreased YAP target gene expression with long-term treatment.
- Knockdown of S1P2 attenuated SPC's anti-proliferative effect and prevented Lats2 upregulation.
- Short-term SPC treatment led to YAP de-phosphorylation and transient target gene expression, indicating initial YAP activation.
- Knockdown of Lats2 or YAP/TAZ did not abolish the anti-proliferative effect of SPC, suggesting the Hippo pathway is not the primary mediator.
Conclusions:
- SPC exhibits a dual regulatory effect on the Hippo-YAP pathway, inducing initial activation followed by inhibition.
- While SPC modulates Hippo signaling components like Lats2 and YAP, these changes do not fully explain its potent anti-proliferative action on breast cancer cells.
- S1P2 receptor signaling is involved in mediating SPC's effects on Hippo pathway activation and proliferation inhibition.
Related Concept Videos
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
IP3/DAG Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Notch Signaling Pathway

